Literature DB >> 25270282

Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.

Ze-wu Li1, Yong-mei Yang, Lu-tao Du, Zhaogang Dong, Li-li Wang, Xin Zhang, Xuan-jun Zhou, Gui-xi Zheng, Ai-lin Qu, Chuan-xin Wang.   

Abstract

The purpose of the study was to investigate microRNA-223 (miR-223) expression in colorectal cancer (CRC) and its relationship with tumorigenesis and disease prognosis. Quantitative real-time PCR was used to measure levels of miR-223 in tumor samples and adjacent non-cancerous tissues from 62 patients undergoing radical resection for the treatment of CRC. The associations between miR-223 expression and patient age, sex, as well as clinicopathologic parameters, such as tumor size, differentiation, location, invasion depth, metastasis, tumor-node-metastasis (TNM) stage, and overall patient survival, were analyzed by Mann-Whitney U and Kruskal-Wallis tests. Kaplan-Meier method and Cox proportional hazards regression analyses were performed to estimate the prognostic factors for patient survival prediction. The expression of miR-223 was significantly upregulated in CRC tissues compared with adjacent non-cancerous tissues (P < 0.05). This overexpression was associated with TNM stage and lymph node and distant metastases, (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with high miR-223 expression had a poorer overall survival (OS) than those with low miR-223 expression (P = 0.002). Univariate analysis revealed a statistically significant correlation between OS and miR-223 level, histology grade, metastasis and TNM stage (P < 0.001). Furthermore, miR-223 levels and histology grade were independently associated with OS (HR 0.204, 95 % CI 0.101-0.415, P < 0.05 and HR 2.252, 95 % CI 1.429-3.546, P < 0.05, respectively). The overexpression of miR-223 may play an important role in the progression of CRC and can be used as an independent factor to determine CRC prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270282     DOI: 10.1007/s12032-014-0256-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia.

Authors:  Keshu Zhou; Shuhua Yi; Zhen Yu; Zengjun Li; Yanying Wang; Dehui Zou; Junyuan Qi; Yaozhong Zhao; Lugui Qiu
Journal:  Leuk Lymphoma       Date:  2012-01-31

Review 2.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.

Authors:  N C Lau; L P Lim; E G Weinstein; D P Bartel
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

6.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.

Authors:  Mirte Mayke Streppel; Shweta Pai; Nathaniel R Campbell; Chaoxin Hu; Shinichi Yabuuchi; Marcia Irene Canto; Jean S Wang; Elizabeth A Montgomery; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2013-06-11       Impact factor: 12.531

9.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

10.  miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.

Authors:  Weiqi Nian; Xujun Ao; Yongzhong Wu; Yi Huang; Jianghe Shao; Yiming Wang; Zhengtang Chen; Fanglin Chen; Donglin Wang
Journal:  Oncol Lett       Date:  2013-06-04       Impact factor: 2.967

View more
  21 in total

1.  GAS5 functions as a ceRNA to regulate hZIP1 expression by sponging miR-223 in clear cell renal cell carcinoma.

Authors:  Xiao Dong; Chuize Kong; Xiankui Liu; Jianbin Bi; Zhenhua Li; Zeliang Li; Yuyan Zhu; Zhe Zhang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer.

Authors:  Leonie Mühlberg; Benjamin Kühnemuth; Eithne Costello; Victoria Shaw; Bence Sipos; Magdalena Huber; Heidi Griesmann; Sebastian Krug; Marvin Schober; Thomas M Gress; Patrick Michl
Journal:  Oncoimmunology       Date:  2016-05-09       Impact factor: 8.110

3.  Circulating Serum miRNAs as Diagnostic Markers for Colorectal Cancer.

Authors:  Abdel-Rahman N Zekri; Amira Salah El-Din Youssef; Mai M Lotfy; Reham Gabr; Ola S Ahmed; Auhood Nassar; Nehal Hussein; Dalia Omran; Eman Medhat; Salam Eid; Marwa Mahmoud Hussein; Maha Yahia Ismail; Faris Q Alenzi; Abeer A Bahnassy
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

Review 4.  MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer.

Authors:  Fangfang Yang; Guoyun Xuan; Yixin Chen; Lichao Cao; Min Zhao; Chen Wang; Erfei Chen
Journal:  Front Cell Dev Biol       Date:  2022-04-08

5.  Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Jia Ma; Binbin Fang; Fanpeng Zeng; Cong Ma; Haijie Pang; Long Cheng; Ying Shi; Hui Wang; Bin Yin; Jun Xia; Zhiwei Wang
Journal:  Oncotarget       Date:  2015-01-30

6.  MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.

Authors:  Guifang Yu; Xuezhu Chen; Shudi Chen; Weipeng Ye; Kailian Hou; Min Liang
Journal:  J Transl Med       Date:  2016-05-05       Impact factor: 5.531

7.  In Silico Study of miRNA Based Gene Regulation, Involved in Solid Cancer, by the Assistance of Argonaute Protein.

Authors:  Surya Narayan Rath; Debasrita Das; V Badireenath Konkimalla; Sukanta Kumar Pradhan
Journal:  Genomics Inform       Date:  2016-09-30

8.  Upregulation of nucleostemin in colorectal cancer and its effects on cell malignancy.

Authors:  Bin Wei; Qiaoying Huang; Xiaogang Zhong
Journal:  Onco Targets Ther       Date:  2015-07-21       Impact factor: 4.147

9.  MicroRNA-223 promotes mast cell apoptosis by targeting the insulin-like growth factor 1 receptor.

Authors:  Haiyan Gao; Huan Deng; Hong Xu; Qianyuan Yang; Yao Zhou; Jiamin Zhang; Deyu Zhao; Feng Liu
Journal:  Exp Ther Med       Date:  2016-04-05       Impact factor: 2.447

10.  miR-223 promotes colon cancer by directly targeting p120 catenin.

Authors:  Liwei Liu; Chao Zhang; Xiyu Li; Wenjia Sun; Shenghui Qin; Lingzhi Qin; Xi Wang
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.